Compare ESP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | ENTX |
|---|---|---|
| Founded | 1928 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 147.4M |
| IPO Year | 1995 | 2015 |
| Metric | ESP | ENTX |
|---|---|---|
| Price | $63.74 | $3.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $64.00 | $9.00 |
| AVG Volume (30 Days) | 29.6K | ★ 3.6M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.74 | 0.22 |
| Revenue | ★ $43,950,872.00 | $42,000.00 |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $22.67 | ★ $14.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.00 | $0.91 |
| 52 Week High | $74.77 | $4.20 |
| Indicator | ESP | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 67.19 |
| Support Level | $54.35 | $1.48 |
| Resistance Level | $67.31 | $4.20 |
| Average True Range (ATR) | 2.11 | 0.24 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 64.52 | 88.24 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.